Heroin remains a major drug of abuse and is preferred by addicts over morphine. Like morphine, heroin has high affinity and selectivity for -receptors, but its residual analgesia in exon 1 MOR-1 knockout mice that do not respond to morphine suggests a different mechanism of action. MOR-1 splice variants lacking exon 1 have been observed in mice, humans, and rats, raising the possibility that they might be responsible for the residual heroin and morphine-6␤-glucuronide (M6G) analgesia in the exon 1 knockout mice. To test this possibility, we disrupted exon 11 of MOR-1, which eliminates all of the variants that do not contain exon 1. Morphine and methadone analgesia in the exon 11 knockout mouse was normal, but the analgesic actions of heroin, M6G, and fentanyl were markedly diminished in the radiant heat tailflick and hot-plate assays. Similarly, the ability of M6G to inhibit gastrointestinal transit was greatly diminished in these exon 11 knockout mice, whereas the ability of morphine was unchanged. These findings identify receptors selectively involved with heroin and M6G actions and confirm the relevance of the exon 11-associated variants and raise important issues regarding the importance of atypical truncated G-protein-coupled receptors.
C
linicians have long appreciated analgesic differences among the -opioid-analgesics, with some patients responding better to one drug than another (1) , results that have been recapitulated in animal models (2, 3) . Heroin remains a major drug of abuse and is preferred by addicts over morphine (4, 5) . Why addicts and patients should be able to distinguish between 2 -agonists that presumably act through only -opioid-receptors is not clear. Although some investigators have favored pharmacokinetic factors, several studies raised the possibility of pharmacodynamic causes (2, 6) . This inability to reconcile the diverse pharmacology of -opioids with their binding selectivity led to the proposal of multiple -opioid-receptors (7), a concept initially proposed based on binding and pharmacological studies in animal models and subsequently confirmed with the identification of a large number of splice variants of the cloned -opioid-receptor MOR-1 in mice, rats, and humans ( Fig. 1A ) (8) (9) (10) (11) (12) (13) (14) (15) .
MOR-1 is essential for morphine actions, as shown by the complete loss of morphine activity in a series of MOR-1 knockout mice (16 -19) . However, detailed studies on one exon 1 knockout mouse revealed persistent heroin and morphine-6␤-glucuronide (M6G) analgesia despite the absence of morphine actions (19) . It has been suggested that heroin could act through ␦-opioid-receptors (20, 21) , raising the possibility that this residual activity ref lected cross-labeling of ␦-or possibly even -receptors. However, this seems unlikely because the residual M6G activity is not reversed by ␦ or antagonists. Alternatively, the drugs could be acting through MOR-1 variants lacking exon 1, such as those we have previously reported in mice ( Fig. 1) (8) and, most recently, in humans (22) . These variants are associated with exon 11, which is located Ϸ30 kb upstream of exon 1 in the mouse and is under the control of its own exon 11 promoter (8, 23) . This possibility was supported by the observation that exon 1 knockout animals that still responded to heroin continued to express mRNA transcripts from the MOR-1 gene (19) . To explore the role of these exon 11-associated variants in heroin and M6G actions, we generated an exon 11 knockout mouse and now report that selective disruption of exon 11 leads to a unique phenotype for -opioids showing a marked reduction of heroin, M6G, and fentanyl actions with little effect on the actions of morphine or methadone.
Results
Exon 11 was targeted in 129/Sv embryonic stem (ES) cells by homologous recombination by using a targeting vector in which exon 11 and its adjacent intron region were replaced by an IRES//LacZ-loxP/tk-neo/loxP cassette ( Fig. 2A) . Transfection of the targeting vector into ES cells yielded 4 positive clones from the 192 neo-resistant clones selected, as determined by Southern blot analysis of EcoRV-digested ES cell DNA by using a 3Ј probe (Fig. 2B) . Two targeted ES clones were used to generate germ-line-transmitting chimeras. Homozygous mice then were produced through heterozygous mating. Heterozygous mating produced 26.2% wild-type mice, 49.2% heterozygotes, and 24.6% homozygotes (n ϭ 309), indicating that mice lacking exon 11 developed normally. Homozygous mice were healthy and fertile with no obvious morphological abnormalities. RT-PCR confirmed the loss of exon 11, revealing a loss of Ϸ58% of the mRNA transcripts containing exon 11 in the heterozygotes compared with wild-type animals and its complete absence in the homozygotes (Fig. 2C) .
The gene encoding MOR-1 has 2 independent promoters. One is located immediately upstream of exon 1, whereas the second is associated with exon 11 and is located Ϸ30 kb upstream of exon 1. To determine the relative contribution of the exon 11-generated variants to total MOR-1 expression, we compared mRNA levels in wild-type and knockout animals with 3 sets of primers spanning exons 1 and 2, 2 and 3, and 3 and 4 by using RT-PCR (Fig. 2D) . The products from the exon 1 and 2 primers revealed a 22% decrease in mRNA levels, whereas the exon 2 and 3 primers showed a decrease of 33% and the exon 3 and 4 primers were lowered by 19%. Thus, the exon 11 promoter appears to be responsible for approximately a quarter of MOR-1 expression at the mRNA level.
We observed a similar loss at the protein level in the exon 11 knockout animals, assessed with receptor binding ( The pharmacological consequences of disrupting exon 11 differed markedly from those observed in earlier studies by using an exon 1 knockout animal (19) . In contrast to the exon 1 knockouts in which morphine was totally inactive, disruption of exon 11 had little effect on analgesia in the radiant heat tail-flick assay for fixed doses of either morphine or methadone (Fig. 3 Upper). However, we observed a decreased response for heroin, M6G, and fentanyl in these same knockout animals (Fig. 3 Upper). Full dose-response curves confirmed these observations ( Table 3 ). Disruption of exon 11 had no significant effect on the analgesic ED 50 value for morphine or methadone. In contrast, the ED 50 values for heroin, M6G, and fentanyl were significantly increased. Inspection of these dose-response curves revealed a parallel shift to the right with no decrease in the maximal response. It was interesting that the heterozygotes showed no decrease in analgesic sensitivity, suggesting the existence of spare receptors. Similar results were observed in a second analgesic test, the hot-plate assay (Fig. 3 Lower) . As in the Comparisons are made by using ANOVA, which demonstrated a significant difference among the groups (P Ͻ0.04) with post hoc Tukey tests confirming that the knockout groups are significantly lower (P Ͻ0.05) than wild-type groups, except for E11 where only the wild-type and heterozygous groups are compared by using a Student's t test (P Ͻ0.02) because there is no observable product in the knockout animals.
tail-flick assay, disruption of exon 11 had no effect on morphine actions while significantly lowering the activity of M6G.
Naloxone (5 mg/kg, s.c.) eliminated the analgesic responses of both drugs in wild-type and knockout mice, documenting the opioid nature of the response (Fig. 4) . Morphine and M6G analgesia in the wild-type mice was mediated through -receptors, as illustrated by the antagonism of analgesia by the mu-selective antagonist ␤-funaltrexamine (␤-FNA) (Fig. 4 ) and the inability of the ␦-antagonist naltrindole and the 1 antagonist to significantly lower the response of morphine, confirming results from the literature. Similarly, ␤-FNA antagonized morphine analgesia in the exon 11 knockout animals, indicating that morphine was still acting through -receptors in the knockout mice. The ability of higher doses of heroin, M6G, and fentanyl to elicit a full analgesic response in the exon 11 knockout mice implied that the higher doses were acting through a secondary receptor system. The reversal of the analgesia produced by the higher M6G doses in these knockout animals by ␤-FNA indicated that this secondary system also involved -opioid-receptors (Fig. 4) .
Phenotypic differences due to the disruption of exon 11 were not limited to analgesia. Opiates slow gastrointestinal transit, an important factor contributing to constipation. In wild-type mice, both morphine and M6G inhibited gastrointestinal transit, decreasing the distance traveled by a charcoal meal by about 75% (Fig. 5) . Disruption of exon 11 did not appreciably alter the ability of morphine to inhibit gastrointestinal transit. In contrast, the inhibition produced by M6G was greatly diminished in the knockout mice. As with analgesia, M6G retained full activity in the heterozygotes, implying the existence of spare receptors.
Discussion
Multiple -opioid-receptors, originally proposed more than 25 years ago (7), have now been confirmed with the cloning of an array of MOR-1 splice variants (Fig. 1) . Early studies established the existence of 3Ј-splicing, with a series of exon 1 variants differing only in their amino acid sequence at the tip of the intracellular C terminus. A second set of 5Ј splice variants associated with exon 11, located about 30 kb upstream of exon 1 and under the control of a physically distinct promoter, illustrates the complex nature of this gene (8) . The current study establishes both the expression and relevance of the exon 11-associated splice variants. These exon (27) . Results are the means Ϯ SEM of at least 3 independent determinations. *The B max values for sites varied significantly in the various groups of animals (P Ͻ 0.0005; ANOVA), with the knockout animals significantly lower than wild-type animals (P Ͻ 0.001) and heterozygous animals (P Ͻ 0.05). Competition studies were carried out in brain membranes from wild-type, heterozygous, and knockout mice with the agonist ([ 3 H]DAMGO), as previously described (27) . IC 50 values were determined and converted to Ki values. Results are the means Ϯ SEM of at least 3 independent determinations. 
11-associated variants represent a significant contribution to total
Oprm gene expression, corresponding to approximately a quarter of the total expression of MOR-1 and its variants at both the mRNA and protein levels in the whole brain. Previously, we observed distinct regional distributions for the exon 11 variants that differed from that of MOR-1 itself (8), implying functional significance. However, the phenotype of the exon 11 knockout mice provides the first documentation of the functional role of this set of MOR-1 variants.
A number of studies have illustrated pharmacological differences between morphine and heroin (2), whereas others clearly established the role of MOR-1 in their actions by using antisense (24, 25) and knockout approaches (16) (17) (18) (19) . However, the mechanisms responsible for heroin and M6G actions were not clear. The current studies demonstrate the importance of the exon 11-associated variants in mediating heroin, M6G, and fentanyl analgesia and provide the first association of specific MOR-1 splice variants with these drug actions. The exon 11 knockout mouse illustrates a unique pharmacological phenotype and how alternative splicing of the -opioid-receptor gene encoding MOR-1 may help explain the behavioral differences among -opioids, including the ability of addicts to discriminate between heroin and morphine (5).
However, the role of the exon 11-associated variants in heroin and M6G actions raises another interesting issue at the molecular level. The exon 11-associated variants that yield full, 7-transmembrane-domain receptors (MOR-1H, MOR-1J, and MOR-1K) contain exon 1. Because heroin and M6G are still active in the exon 1 knockout mice, these variants are not likely to play a major role in the actions of these drugs. Of the 5 remaining exon 11-associated variants that lack exon 1, three (MOR-1G, MOR-1M, and MOR-1N) have been demonstrated in the brain by Western blot and RT-PCR. However, these 3 exon 11-associated variants are structurally unique. They contain only the 6 transmembrane domains encoded by exons 2 and 3. Although there always remains the possibility that additional exon 11 variants lacking exon 1, and which possess a full complement of 7 transmembrane domains, remain to be identified, the evidence currently available suggests that the truncated proteins are pharmacologically active. This possibility is further supported by the continued expression of exon 11 variants in the Pintar exon 1 knockout mouse.
In conclusion, MOR-1 knockout animals have yielded many insights into the actions of opioid analgesics. The disruption of exon Analgesia was assessed in cumulative dose-response studies with at least 8 animals/groups using the radiant heat tail-flick assay and was defined quantally as a doubling or greater of the baseline latency with a maximal latency of 10 sec to minimize tissue damage, as previously described (28) . ED 50 values were determined using probit analysis. Results are the means Ϯ SEM of the ED 50 values determined from independent dose-response studies for morphine (n ϭ 5), methadone (n ϭ 5), heroin (n ϭ 7), M6G (n ϭ 7), and fentanyl (n ϭ 4). Differences among groups for each drug were determined by ANOVA. 5 . Effects of disruption of exon 11 on gastrointestinal transit. Groups of mice (n ϭ 6 -8) receive morphine (4.5 mg/kg, s.c.) or M6G (4.5 mg/kg) 15 min before a 0.5-ml charcoal meal (2.5% gum tragacanth in 10% activated charcoal in water), and are killed 30 min later, and the distance the charcoal traveled is measured. Results are analyzed by using 2-way ANOVA (P Ͻ 0.001). The response in the morphine groups are significantly lower than saline in all 3 groups of mice (P Ͻ 0.001 in all groups). The response in the M6G group is significantly lower than saline in wild-type (P Ͻ 0.001), heterozygous (P Ͻ 0.001), and knockout (P Ͻ 0.01) mice. The response in the morphine group is not significantly different from that of M6G in saline or heterozygous groups, but is significantly different in the knockout group (P Ͻ 0.001).
11 generated an analgesic phenotype unlike that seen with the exon 1 knockout and establishes a role for the exon 11-associated variants in heroin action. In addition to providing potential insights into the clinical effects of these agents, the observations also open questions into the potential functional significance of truncated splice variants that may extrapolate to other G-protein coupled receptors, many of which also express truncated forms.
Experimental Procedures
Construction of the E11 Knockin/Knockout (KI/KO) Targeting Vector. A 1.1-kb fragment was amplified by PCR with a sense primer containing a NcoI site (5Ј-GAA CCA CCA TGG CTG AGC CCC GCC AGG AGT TCG ACG-3Ј) and an antisense primer containing a BamHI site (5Ј-GAT GGG ATC CCC GGA CAC GAT CTC CGC CCC GTG GTC GGT CTT GG-3Ј) using the first-cDNA synthesized from bovine brain mRNA (Clontech) as the template. A 0.6-kb EcoRI/NcoI IRES fragment cut from a IRES//LacZ/LTNL cassette (a kind gift from Peter Mombaerts, The Rockefeller University), and the 1.1-kb NcoI/BamHI fragment were subcloned into EcoRI/BamHI site of pcDNA3(Ϫ) to construct IRES//pcDNA3(Ϫ). A 3.1-kb LacZ fragment cut from pMC1871 vector (Amersham Pharmacia) was inserted into the BamHI site of IRES//pcDNA3(Ϫ) to make IRES//LacZ/pcDNA3(Ϫ), in which the was in frame with LacZ. A 3.7-kb KpnI/XhoIfragmentcontaining5ЈofE11digestedfrompSP1thatwasamplifiedfrom a ES-129svJ-derived genomic BAC clone (GenomeSystems) was subcloned into KpnI/ XhoI sites of pBluescript SKII vector containing a unique polyliner (PacI-AscI-FseI-NheIAflII) to make 5Ј-arm/SK. The IRES//LacZ cassette cut from IRES//LacZ/pcDNA3(Ϫ) with XhoI/AflII was subcloned into XhoI/AflII sites of 5Ј-arm/SK to make 5Ј-arm/IRES/ /LacZ/SK. A 2-kb XbaI loxP-pgk/neo-loxP fragment cut from loxP-pgk/neo-loxP/ pGEM7 (a kind gift from Qin Wen Yang, The Rockefeller University) was then subcloned into NheI site of 5Ј-arm/IRES//LacZ/SK to make 5Ј-arm/IRES//LacZ/loxPpgk/neo-loxP/SK. Finally, a 2-kb FseI/AscI genomic fragment containing 3Ј of E11 amplified by PCR with a sense primer containing a FseI site (5Ј-GAT CTT GGC CGG CCT CTTGTTCTCGTGGCTGTATTGGGC-3Ј)andanantisenseprimercontainingaAscIsite (5Ј-GAT CTT GGC GCG CCT TTA GAG CTG GTT AAA TCC CAT GCT CTA G-3Ј) by using genomic DNA from 129/Sv ES cells, was subcloned into FseI/AscI sites of 5Ј-arm/IRES/ /LacZ/loxP-pgk/neo-loxP/SK to make the complete targeting construct (Fig. 1A) . All of the PCR products and cloning junctions were verified by sequencing with appropriate primers.
Generation of E11 KI/KO Mice. Forty micrograms of the targeting vector was linearized with AscI, and electroporated into 1 ϫ 10 6 ES cells at 800 V and 3 F with a Bio-Rad GenePulser. G418-resistant colonies were picked after 7 to 8 days selection with 150 g/ml G418. Genomic DNA purified from G418-resistant cells was digested with EcoRV and screened by Southern blot analysis with a 0.7-kb external 3Ј probe. Four positives out of 196 G418-resistant clones were identified. Southern blot analysis with several restriction enzymes by using a 3Ј probe and a tk-neo probe further verified single-copy integration of the targeting vector in the correct locus. Two positive ES clones were injected into C57BL/6 blastocysts to produce chimeras, which then were bred with C57BL/6. Offspring of the chimeras were genotyped by Southern blot analysis of tail DNAs by using the 3Ј probe.
RT-PCR.
Total RNA was extracted from mouse brain with the guanidinium thiocyanate/phenol/chloroform extraction method (26) , treated with DNase I by using TURBO DNA-free reagents (Ambion) to remove potentially contaminating genomic DNA, and reversed transcribed with random hexamer or oligo(dT) and SuperScript II reverse transcriptase (Invitrogen) as previously described (9) . The reverse transcriptase product was treated with RNase H to remove RNA complementary to the first-strand cDNA. The first-strand cDNA was then used as a template in PCRc to amplify a 173-bp exon 11 fragment with a sense primer (5Ј-GTCCTTGAGAATGGAGAGGATCAGCAAAGC-3Ј) and an antisense primer (5Ј-GGTAACTCTTCCCCTCTTGATTTCCATC 3Ј), a 402-bp fragment for exons 1 and 2 with a sense primer (5Ј-GGCTCCTGGCTCAACTTGTCCCAC-3Ј) and an antisense primer (5Ј-GGTGCAGAGGGTGAAGATACTGGTGAAC-3Ј), a 561-bp fragment for exons 2 and 3 with a sense primer (5Ј-GTGTTAACTACCTGATGGGAACGTGGC-3Ј) and an antisense primer (5Ј-GTGGTTTCTGGAATCGTGATCAGTGC-3Ј), and a 449-bp fragment for exons 3 and 4 with a sense primer (5Ј-GCACTGATCACGAT-TCCAGAAACCAC-3Ј) and an antisense primer (5Ј-CTGACGTGTAGCGTGAATAGC-CAGAGAGG-3Ј). RNA loading was estimated by a parallel PCR with a pair of glyceraldehyde-3-phosphate dehydrogenase (G3PDH) (Clontech). PCRs were carried out by using Platinum TaqDNA polymerase (Invitrogen) for 28 -45 cycles after 2 min at 94°C, each cycle consisting of a 20-sec denaturing step at 94°C, a 20-sec annealing step at 65°C, and a 45-to 90-sec extension at 72°C. The PCR products were analyzed in 1.5% agarose gel, stained with ethidium bromide and photographed with FluorChem 8000 Image system (Alpha Innotech). The relative band intensities from the gel were quantified with AlphaEase FC software and normalized with the intensities from G3PDH bands. To quantify the amount of transcripts from different targets with a wide range of abundance, various PCR cycle numbers and extension times were adjusted to amplify cDNA at linear phase. For lower abundant exon 11, we used 45 cycles/45 sec extension. For medium abundant exons 1/2, 2/3, and 3/4, we amplified for 35 cycles/45 sec. For higher abundant G3PDH transcript, we only used 28 cycles/90 sec extension.
Receptor Binding Assays. Membranes were prepared from mouse brain and assays conducted as described previously (27) Tail-Flick and Hot-Plate Assays. All behavioral studies were performed with mice generated from heterozygous ϫ heterozygous matings to provide wild-type, heterozygous, and homozygous animals with comparable genetic backgrounds. In the radiant heat tail-flick assay, analgesia was determined quantally as a doubling or greater of baseline tail-flick latencies. A maximal latency of 10 sec was used to minimize tissue damage. Cumulative dose-response curves were determined by starting all mice at the lowest opioid dose and escalating the dose. Mice that showed analgesia were removed from further testing and carried forward as analgesic. ED50 values for each replication was calculated by using probit analysis. Results are the mean Ϯ SEM of 4 to 7 independent ED50 determinations, each with groups of at least 6 mice, as indicated. ED50 values among the groups were compared by ANOVA followed by Tukey's post hoc test.
To examine the effects of opioid antagonists, groups of mice received the indicated antagonist 15 min before the agonist, with the exception of ␤-funaltrexamine, which was administered 24 h before the agonist.
The hot-plate assay was performed at 52°C. The time(s) elapsing to the first pain response (licking or jumping) was scored. A maximal latency of 30 sec was used to minimize any tissue damage. Results were determined as %MPE ([latency after drug Ϫ baseline latency]/[30 Ϫ baseline latency]).
Gastrointestinal Transit. Gastrointestinal transit was assessed as previously described (29) . Groups of mice (n ϭ 6 -8) were treated with the indicated drugs 15 min before administering a 0.5-ml charcoal meal (2.5% gum tragacanth in 10% activated charcoal in water) by oral gavage. The mice were killed 30 min later and the distance the charcoal traveled was measured. Results are presented as the means Ϯ SEM for each group.
Statistics. Analgesia was assessed quantally and analyzed by using the Fisher exact test. Other comparisons were made by using either Student's t test or analysis of variance, depending on the comparison.
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